Novel Imaging of Prostate Cancer with MRI, MRI/US, and PET
暂无分享,去创建一个
Jennifer J Kwak | Phillip J Koo | Peter L Choyke | P. Choyke | S. Pokharel | J. Kwak | P. Koo | Sajal Pokharel
[1] P. Choyke,et al. Anti-1-Amino-3-F-18-Fluorocyclobutane-1-Carboxylic Acid: Physiologic Uptake Patterns, Incidental Findings, and Variants That May Simulate Disease , 2014 .
[2] J. Votaw,et al. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] S. Ramin,et al. Application of 11C‐acetate positron‐emission tomography (PET) imaging in prostate cancer: systematic review and meta‐analysis of the literature , 2013, BJU international.
[4] H. Scher,et al. Targeting the androgen receptor pathway in prostate cancer. , 2008, Current opinion in pharmacology.
[5] R. Lenkinski,et al. Central gland and peripheral zone prostate tumors have significantly different quantitative imaging signatures on 3 tesla endorectal, in vivo T2‐weighted MR imagery , 2012, Journal of magnetic resonance imaging : JMRI.
[6] J. Fütterer,et al. ESUR prostate MR guidelines 2012 , 2012, European Radiology.
[7] T. Shiga,et al. Accumulation of [11C]acetate in normal prostate and benign prostatic hyperplasia: comparison with prostate cancer , 2002, European Journal of Nuclear Medicine and Molecular Imaging.
[8] I. Jambor,et al. In Vivo Imaging of Prostate Cancer Using [68Ga]-Labeled Bombesin Analog BAY86-7548 , 2013, Clinical Cancer Research.
[9] P. P. Iu,et al. ESUR prostate MR guidelines. , 2013, European radiology.
[10] J. Humm,et al. Pharmacokinetic Assessment of the Uptake of 16β-18F-Fluoro-5α-Dihydrotestosterone (FDHT) in Prostate Tumors as Measured by PET , 2010, Journal of Nuclear Medicine.
[11] J. Nelson,et al. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model , 2003, The Prostate.
[12] P. Nelson,et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. , 2008, Cancer research.
[13] H. Jadvar. Prostate Cancer: PET with 18F-FDG, 18F- or 11C-Acetate, and 18F- or 11C-Choline , 2011, The Journal of Nuclear Medicine.
[14] M. Morris,et al. Novel Tracers and Their Development for the Imaging of Metastatic Prostate Cancer* , 2008, Journal of Nuclear Medicine.
[15] A. Kibel,et al. 11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction , 2013, The Journal of Nuclear Medicine.
[16] L. Bu,et al. A Comparative Study of Radiolabeled Bombesin Analogs for the PET Imaging of Prostate Cancer , 2013, The Journal of Nuclear Medicine.
[17] H. Jadvar. Molecular imaging of prostate cancer: PET radiotracers. , 2012, AJR. American journal of roentgenology.
[18] W. Lowrance,et al. Castration-resistant prostate cancer: AUA Guideline. , 2013, The Journal of urology.
[19] G. Slegers,et al. Is there a role for agonist gastrin-releasing peptide receptor radioligands in tumour imaging? , 2001, Nuclear medicine communications.
[20] Andrew B Rosenkrantz,et al. Optimization of prostate biopsy: the role of magnetic resonance imaging targeted biopsy in detection, localization and risk assessment. , 2014, The Journal of urology.
[21] H. Shinmoto,et al. Diffusion kurtosis imaging study of prostate cancer: Preliminary findings , 2014, Journal of magnetic resonance imaging : JMRI.
[22] C. Cordon-Cardo,et al. Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.
[23] C. Dence,et al. Positron tomographic assessment of androgen receptors in prostatic carcinoma , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[24] E. Crawford,et al. The Accuracy of Prostate Cancer Localization Diagnosed on Transrectal Ultrasound-Guided Biopsy Compared to 3-Dimensional Transperineal Approach , 2013, Advances in urology.
[25] A. Fenster,et al. Evaluation of MRI-TRUS fusion versus cognitive registration accuracy for MRI-targeted, TRUS-guided prostate biopsy. , 2015, AJR. American journal of roentgenology.
[26] Steve Y. Cho,et al. New Agents and Techniques for Imaging Prostate Cancer , 2009, Journal of Nuclear Medicine.
[27] Bachir Taouli,et al. Body diffusion kurtosis imaging: Basic principles, applications, and considerations for clinical practice , 2015, Journal of magnetic resonance imaging : JMRI.
[28] Pingkun Yan,et al. Magnetic resonance imaging/ultrasound fusion guided prostate biopsy improves cancer detection following transrectal ultrasound biopsy and correlates with multiparametric magnetic resonance imaging. , 2011, The Journal of urology.
[29] Hossein Jadvar,et al. Molecular Imaging of Prostate Cancer with PET , 2013, The Journal of Nuclear Medicine.
[30] C W Piccoli,et al. Staging of prostate cancer: results of Radiology Diagnostic Oncology Group project comparison of three MR imaging techniques. , 1994, Radiology.
[31] I. Burger,et al. Dosimetry and First Clinical Evaluation of the New 18F-Radiolabeled Bombesin Analogue BAY 864367 in Patients with Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[32] George Sgouros,et al. Biodistribution, Tumor Detection, and Radiation Dosimetry of 18F-DCFBC, a Low-Molecular-Weight Inhibitor of Prostate-Specific Membrane Antigen, in Patients with Metastatic Prostate Cancer , 2012, The Journal of Nuclear Medicine.
[33] U. Haberkorn,et al. Preclinical Evaluation of a Tailor-Made DOTA-Conjugated PSMA Inhibitor with Optimized Linker Moiety for Imaging and Endoradiotherapy of Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[34] Ji-gang Yang,et al. The value of anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT in the diagnosis of recurrent prostate carcinoma: a meta-analysis , 2016, Acta radiologica.
[35] W. Heston,et al. Tumor target prostate specific membrane antigen (PSMA) and its regulation in prostate cancer , 2004, Journal of cellular biochemistry.
[36] F. Bladou,et al. Accuracy of cognitive MRI-targeted biopsy in hitting prostate cancer-positive regions of interest , 2015, World Journal of Urology.
[37] S. Kridel,et al. 1-11C-Acetate as a PET Radiopharmaceutical for Imaging Fatty Acid Synthase Expression in Prostate Cancer , 2008, Journal of Nuclear Medicine.
[38] J. Nesland,et al. Transperineal prostate biopsy detects significant cancer in patients with elevated prostate‐specific antigen (PSA) levels and previous negative transrectal biopsies , 2012, BJU international.
[39] F. Bowman,et al. Anti-3-[(18)F]FACBC positron emission tomography-computerized tomography and (111)In-capromab pendetide single photon emission computerized tomography-computerized tomography for recurrent prostate carcinoma: results of a prospective clinical trial. , 2014, The Journal of urology.
[40] Marc Lemort,et al. MRI-Targeted Biopsies versus Systematic Transrectal Ultrasound Guided Biopsies for the Diagnosis of Localized Prostate Cancer in Biopsy Naïve Men , 2015, BioMed research international.
[41] P. Larson,et al. Metabolic Imaging of Patients with Prostate Cancer Using Hyperpolarized [1-13C]Pyruvate , 2013, Science Translational Medicine.
[42] Kemal Tuncali,et al. Transperineal in-bore 3-T MR imaging-guided prostate biopsy: a prospective clinical observational study. , 2015, Radiology.
[43] Magnus Dahlbom,et al. Radiation dose estimates in humans for (11)C-acetate whole-body PET. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[44] G Nilsson,et al. Characterization of a gastrin releasing peptide from porcine non-antral gastric tissue. , 1979, Biochemical and biophysical research communications.
[45] V. Erspamer,et al. Isolation and structure of bombesin and alytesin, two analogous active peptides from the skin of the european amphibiansBombina andAlytes , 1971, Experientia.
[46] D. Nieboer,et al. Magnetic resonance imaging-targeted biopsy may enhance the diagnostic accuracy of significant prostate cancer detection compared to standard transrectal ultrasound-guided biopsy: a systematic review and meta-analysis. , 2015, European urology.
[47] S. Mather,et al. Targeting prostate cancer with radiolabelled bombesins , 2006, Cancer imaging : the official publication of the International Cancer Imaging Society.
[48] M. Schwaiger,et al. Evaluation of Hybrid 68Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy , 2015, The Journal of Nuclear Medicine.
[49] E J Halpern,et al. Using gray-scale and color and power Doppler sonography to detect prostatic cancer. , 2000, AJR. American journal of roentgenology.
[50] S. Balk,et al. Mechanisms mediating androgen receptor reactivation after castration. , 2009, Urologic oncology.
[51] Toby C. Cornish,et al. 18F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[52] Baris Turkbey,et al. Comparison of MR/ultrasound fusion-guided biopsy with ultrasound-guided biopsy for the diagnosis of prostate cancer. , 2015, JAMA.
[53] G. Baldwin,et al. Expression and function of gastrin‐releasing peptide (GRP) in normal and cancerous urological tissues , 2014, BJU international.
[54] F DuBois Bowman,et al. Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. , 2007, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[55] Mark Emberton,et al. Image-guided prostate biopsy using magnetic resonance imaging-derived targets: a systematic review. , 2013, European urology.
[56] H. Scher,et al. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] Jurgen J Fütterer,et al. Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.
[58] Martin G Pomper,et al. PET imaging in prostate cancer: focus on prostate-specific membrane antigen. , 2013, Current topics in medicinal chemistry.
[59] Y. Yamashita,et al. Ultra-high-b-value diffusion-weighted MR imaging for the detection of prostate cancer: evaluation in 201 cases with histopathological correlation , 2010, European Radiology.
[60] J. Habener,et al. Cloning and characterization of cDNAs encoding human gastrin-releasing peptide. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[61] Katarzyna J Macura,et al. Prostate cancer: sextant localization at MR imaging and MR spectroscopic imaging before prostatectomy--results of ACRIN prospective multi-institutional clinicopathologic study. , 2009, Radiology.
[62] E. Crawford,et al. Challenges and recommendations for early identification of metastatic disease in prostate cancer. , 2014, Urology.
[63] Y. Liu,et al. Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer , 2006, Prostate Cancer and Prostatic Diseases.
[64] Pierre Mozer,et al. First round of targeted biopsies using magnetic resonance imaging/ultrasonography fusion compared with conventional transrectal ultrasonography‐guided biopsies for the diagnosis of localised prostate cancer , 2015, BJU international.
[65] M J Bronskill,et al. Magnetic resonance imaging of the prostate. , 1985, Radiology.
[66] Y. Erdi,et al. Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer , 2004 .
[67] Heinz-Peter Schlemmer,et al. Comparative analysis of transperineal template saturation prostate biopsy versus magnetic resonance imaging targeted biopsy with magnetic resonance imaging-ultrasound fusion guidance. , 2015, The Journal of urology.
[68] Mohammad H. Mahoor,et al. Diagnosis of prostatic Carcinoma on multiparametric magnetic resonance imaging using shearlet transform , 2014, 2014 36th Annual International Conference of the IEEE Engineering in Medicine and Biology Society.
[69] N. Shikano,et al. Putative Transport Mechanism and Intracellular Fate of Trans-1-Amino-3-18F-Fluorocyclobutanecarboxylic Acid in Human Prostate Cancer , 2011, Journal of Nuclear Medicine.
[70] G. Koning,et al. A Novel 111In-Labeled Anti–Prostate-Specific Membrane Antigen Nanobody for Targeted SPECT/CT Imaging of Prostate Cancer , 2015, The Journal of Nuclear Medicine.
[71] Baris Turkbey,et al. Comparison of calculated and acquired high b value diffusion-weighted imaging in prostate cancer , 2015, Abdominal Imaging.
[72] P. Choyke,et al. Localized prostate cancer detection with 18F FACBC PET/CT: comparison with MR imaging and histopathologic analysis. , 2014, Radiology.
[73] W. Oyen,et al. Molecular Imaging of Prostate Cancer: Tapping into the Opportunities , 2015, The Journal of Nuclear Medicine.
[74] H. Kung,et al. Oncogenic activation of androgen receptor. , 2009, Urologic oncology.
[75] John Kurhanewicz,et al. Hyperpolarized 13C MR for Molecular Imaging of Prostate Cancer , 2014, The Journal of Nuclear Medicine.
[76] Serge K. Lyashchenko,et al. A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. , 2014, The Journal of urology.
[77] Jin Tae Kwak,et al. Automated prostate cancer detection using T2-weighted and high-b-value diffusion-weighted magnetic resonance imaging. , 2015, Medical physics.
[78] Jens Sörensen,et al. [18F]Fluoroacetate is not a functional analogue of [11C]acetate in normal physiology , 2009, European Journal of Nuclear Medicine and Molecular Imaging.